Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51788
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12491]
Metadata
Show full item record
PERSPECTIVES FOR A NEW DRUG CANDIDATE FOR CHAGAS DISEASE THERAPY
Quimioterapia experimental
Doença de Chagas
Candidatos a drogas
Prova de conceito
Inibidores da Fosfodiesterase
Experimental chemotherapy
Chagas disease
Drug candidates
Proof of concept
Phosphodiesterase inhibitors
Soeiro, Maria de Nazaré Correia | Date Issued:
2022
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Biologia Celular. Rio de Janeiro, RJ, Brasil.
Abstract
Chagas disease (CD), a neglected tropical illness caused by the protozoan Trypanosoma cruzi, affects more than 6 million people mostly in poor areas of Latin America. CD has two phases: an acute, short phase mainly oligosymptomatic followed to the chronic phase, a long-lasting stage that may trigger cardiac and/or digestive disorders and death. Only two old drugs are available and both present low efficacy in the chronic stage, display side effects and are inactive against parasite strains naturally resistant to these nitroderivatives. These shortcomings justify the search for novel therapeutic options considering the target product profile for CD that will be presently reviewed besides briefly revisiting the data on phosphodiesterase inhibitors upon T. cruzi.
Keywords in Portuguese
Trypanosoma cruziQuimioterapia experimental
Doença de Chagas
Candidatos a drogas
Prova de conceito
Inibidores da Fosfodiesterase
Keywords
Trypanosoma cruziExperimental chemotherapy
Chagas disease
Drug candidates
Proof of concept
Phosphodiesterase inhibitors
Share